Biotechnology company OmniAb on Tuesday raised its cash flow guidance for 2026, citing increased licensing activity and partnerships. The company did not disclose the new forecast in its announcement.
OmniAb, which develops antibody discovery platforms for drug development, said the upward revision reflects a "strong pipeline of licensing agreements" and growing demand from pharmaceutical partners. The move follows a period of heightened collaboration within the sector as drugmakers seek innovative biologics to address unmet medical needs.
Financial terms of the licensing deals were not specified. OmniAb’s prior guidance for 2026 cash flow had not been publicly disclosed, limiting direct comparison with the revised outlook. The company’s shares rose 3% in after-hours trading following the announcement.
OmniAb’s antibody platforms are used by major pharmaceutical firms to accelerate drug discovery, including treatments for cancer and autoimmune diseases. The company has expanded its partnerships in recent quarters, including agreements with undisclosed partners in North America and Europe.
Analysts noted that the raised guidance signals confidence in OmniAb’s commercial strategy, though they cautioned that execution risks remain tied to the timing and terms of future licensing deals. The company is scheduled to release its next financial update in conjunction with its full-year earnings report.
The revision underscores the broader trend of biotech firms leveraging licensing revenue as a key driver of profitability amid volatile equity markets and funding pressures.
